PULSE-trial: Summarising the Clinical Outcomes and Benefits of iVAC 2L ® in Clinical Practice: An Expert Discussion with Prof Nicolas van Mieghem
Published: 25 October 2021
Part 1 | Session 1 PULSE-trial: Summarising the Clinical Outcomes and Benefits of iVAC 2L ® in clinical practice Nicolas M Van Mieghem
Part 2 | Session 4 Key Findings: Clinical Experience high-risk PCI next generation MCS protected in Erasmus MC Nicolas M Van Mieghem
In this video series, Professor Nicolas van Mieghem will discuss the benefits of iVAC 2L ® in clinical practice and will share the learnings and key outcomes from the Pulse Trial, and the effect of next generation pulsatile mechanical circulatory support (MCS).
This video is supported by PulseCath in collaboration with their co-sponsors: CardiRad, Sanomed, LeviBio, Thomy F.E., Sonimed and Dot Medical.
Key Learning Objectives
- Learn when to use the short term percutaneous ventricular assist device (pVAD), iVAC 2L ® in clinical practice
- Understand the differences between pulsatile and continuous flow
- Understand the technology behind the device
- Gain a better understanding of how the iVAC 2L ® is more efficient
- Learn how to identify the right patient (HR PCI)
- Learn when to use iVAC 2L ® vs Impella
- Further understanding of large bore access management
- Interventional Cardiologists
- Cardiac Surgeons
- Cardiac Nurses
- Cath Lab Nurses
- ICU Doctors
- Cath Lab Technicians
More from this programme
Full Programme - PULSE-trial: Summarising the Clinical Outcomes and Benefits of iVAC 2L ® in Clinical Practice: An Expert Discussion with Prof Nicolas van Mieghem
Chapters of Programme - PULSE-trial: Summarising the Clinical Outcomes and Benefits of iVAC 2L ® in Clinical Practice: An Expert Discussion with Prof Nicolas van Mieghem
Nicolas M Van Mieghem
From an early age, Professor Nicolas Maria Van Mieghem decided to pursue a career that would help others. “I enjoy the feeling of being able to help someone or do something important for them. I wanted to enter a profession that would channel my energy— I was always a busy child,” he says.
A budding athlete, he was a member of Belgium’s national swimming team but soon realized that medicine was his true calling. His father was a general cardiologist and one of his biggest influences early in his career.
Professor Van Mieghem initially intended to train as a cardiac surgeon but decided to specialise in interventional cardiology instead, following advice from a mentor. This decision was cemented when he read the first-in-human case report of transcatheter aortic valve implantation (TAVI) in Circulation by Alain Cribier in 2002.
His mantra is mens sana in corpore sano (a…